|Table of Contents|

Research progress of sentinel lymph node biopsy in axillary management for early breast cancer patients

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 03
Page:
548-551
Research Field:
Publishing date:

Info

Title:
Research progress of sentinel lymph node biopsy in axillary management for early breast cancer patients
Author(s):
LIANG Liang1; ZENG Furen1; YANG Hong1; SHU Yongfeng2
1.Department of Oncology,Hunan Provincial People's Hospital（the First Affiliated Hospital of Hunan Normal University）,Hunan Changsha 410002,China；2.Tongling Integrated Chinese and Western Medicine Hospital，Anhui Tongling 244000，China．
Keywords:
breast neoplasms; sentinel lymph node biopsy; axillary lymph node dissection; tumor adjuvant therapy
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2022.03.036
Abstract:
Traditionally,axillary lymph node dissection(ALND)is the standard treatment for patients with sentinel lymph node-positive breast cancer,while ALND tends to cause upper limb edema,dysfunction and other postoperative complications,which affect the quality of life of patients.Studies in recent years have shown that not all patients need ALND for SLN-positive early breast cancer.For early breast cancers patients who with micrometastasis and 1-2 SLN-positive,omitting ALND dose not affect overall survival.For breast cancer patients with positive clinical axillary lymph nodes,after the clinical axillary lymph nodes turn to the negative through neoadjuvant chemotherapy,whether SLNB can accurately assess the status of axillary lymph nodes is still controversial.This article will summarize the latest literature on breast cancer axillary treatment,and the therapeutic strategies for early breast cancer patients with positive sentinel lymph nodes and the clinical feasibility of SLNB after neoadjuvant chemotherapy for clinical lymph node positive breast cancer are reviewed.

References:

[1]张丽娟,张惠婷,张慧珍,等.乳腺癌术后上肢淋巴水肿患者焦虑抑郁与生活质量状况及其相关性研究［J］.现代临床护理,2021,20(02):15-20. ZHANG LJ,ZHANG HT,ZHANG HZ,et al.Correlation between anxiety and depression and quality of life in patients with upper extremity lymphedema after breast cancer surgery.［J］.Modern Clinical Nursing,2021,20(02):15-20.
[2]马小开,黄建康,王万霞,等.乳腺癌术后上肢淋巴水肿发病的危险因素［J］.中华疾病控制杂志,2020,24(07):856-859. MA XK,HUANG JK,WANG WX,et al.Analysis of the incidence and risk factors of breast cancer－related upper limb lymphedema in post-operative patients［J］.Chinese Journal of Disease Control & Prevention,2020,24(07):856-859.
[3]GIULIANO AE,BALLMAN K,MCCALL L,et al.Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases:long-term follow-up from the american college of surgeons oncology group(Alliance)ACOSOG Z0011 randomized trial［J］.Ann Surg,2016,264(3):413-420.
[4]GALIMBERTI V,COLE BF,ZURRIDA S,et al.Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases(IBCSG 23-01):a phase 3 randomised controlled trial［J］.Lancet Oncol,2013,14(4):297-305.
[5]SOLA M,ALBERRO JA,FRAILE M,et al.Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis:final results from the multicenter clinical trial AATRM 048/13/2000［J］.Ann Surg Oncol,2013,20(1):120-127.
[6]KURU B,YURUKER S,SULLU Y,et al.Management of the Axilla in T1-2 breast cancer patients with macrometastatic sentinel node involvement who underwent breast-conserving therapy［J］.J Invest Surg,2019,32(1):48-54.
[7]SEKINE C,NAKANO S,MIBU A,et al.Breast cancer hormone receptor negativity,triple-negative type,mastectomy and not receiving adjuvant radiotherapy were associated with axillary recurrence after sentinel lymph node biopsy［J］.Asian J Surg,2019,43(1):148-153.
[8]DONKER M,VAN TIENHOVEN G,STRAVER ME,et al.Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer(EORTC 10981-22023 AMAROS):a randomised,multicentre,open-label,phase 3 non-inferiority trial［J］.Lancet Oncol,2014,15(12):1303-1310.
[9]SAVOLT A,PELEY G,POLGAR C,et al.Eight-year follow up result of the OTOASOR trial:The optimal treatment of the axilla-surgery or radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer:A randomized,single centre,phase Ⅲ,non-inferiority trial［J］.Eur J Surg Oncol,2017,43(4):672-679.
[10]VAN DER HEIDEN-VAN DER LOO M,DE MUNCK L,SONKE GS,et al.Population based study on sentinel node biopsy before or after neoadjuvant chemotherapy in clinically node negative breast cancer patients:Identification rate and influence on axillary treatment［J］.Eur J Cancer,2015,51(8):915-921.
[11]KOOTSTRA JJ,DIJKSTRA PU,RIETMAN H,et al.A longitudinal study of shoulder and arm morbidity in breast cancer survivors 7 years after sentinel lymph node biopsy or axillary lymph node dissection［J］.Breast Cancer Res Treat,2013,139(1):125-134.
[12]KRAG DN,ANDERSON SJ,JULIAN TB,et al.Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer:overall survival findings from the NSABP B-32 randomised phase 3 trial［J］.Lancet Oncol,2010,11(10):927-933.
[13]GRADISHAR WJ,MORAN MS,ABRAHAM J,et al.NCCN Guidelines insights:breast cancer,version 4.2021［J］.J Natl Compr Canc Netw,2021,19(5):484-493.
[14]GIULIANO AE,HUNT KK,BALLMAN KV,et al.Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis:a randomized clinical trial［J］.JAMA,2011,305(6):569-575.
[15]GUTH U,MYRICK ME,VIEHL CT,et al.The post ACOSOG Z0011 era:does our new understanding of breast cancer really change clinical practice［J］.Eur J Surg Oncol,2012,38(8):645-650.
[16]刘淼,王殊,彭媛,等.ACOSOG Z0011试验标准用于中国前哨淋巴结阳性乳腺癌患者以避免腋窝淋巴结清扫的可行性研究［J］.中国癌症杂志,2015,25(2):135-140. LIU M,WANG S,PENG Y,et al.The exportability of the criteria defined by Z0011 trial for selecting patients who are eligible for omitting ALND after a positive SLNB result in China［J］.Chinese Journal of Cancer,2015,25(2):135-140.
[17]JUNG J,HAN W,LEE ES,et al.Retrospectively validating the results of the ACOSOG Z0011 trial in a large Asian Z0011-eligible cohort［J］.Breast Cancer Res Treat,2019,175(1):203-215.
[18]PENG Y,LIU M,LI X,et al.Application of the ACOSOG Z0011 criteria to Chinese patients with breast cancer:a prospective study［J］.World J Surg Oncol,2021,19(1):128.
[19]HUANG TW,KUO KN,CHEN KH,et al.Recommendation for axillary lymph node dissection in women with early breast cancer and sentinel node metastasis:A systematic review and meta-analysis of randomized controlled trials using the GRADE system［J］.Int J Surg,2016,34:73-80.
[20]LI CZ,ZHANG P,LI RW,et al.Axillary lymph node dissection versus sentinel lymph node biopsy alone for early breast cancer with sentinel node metastasis:A meta-analysis［J］.Eur J Surg Oncol,2015,41(8):958-966.
[21] GALIMBERTI V,COLE BF,VIALE G,et al.Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases(IBCSG 23-01):10-year follow-up of a randomised,controlled phase 3 trial［J］.Lancet Oncol,2018,19(10):1385-1393.
[22]BONNEAU C,HEQUET D,ESTEVEZ JP,et al.Impact of axillary dissection in women with invasive breast cancer who do not fit the Z0011 ACOSOG trial because of three or more metastatic sentinel lymph nodes［J］.Eur J Surg Oncol,2015,41(8):998-1004.
[23]张丽,俞晓立,郭小毛.前哨淋巴结1～2个阳性早期乳腺癌患者腋窝淋巴结管理办法研究进展［J］.中华放射肿瘤学杂志,2016,25(3):292-295. ZHANG L,YU XL,GUO XM.Research progress of axillary management approach for 1~2 sentinel lymph node positive early stage breast cancer patients［J］.Chinese Jjournal of Radiation Oncology,2016,25(3):292-295.
[24]TAMAYO CARABANO D,ALVAREZ PEREZ R,DE BONILLA DAMIA A,et al.Sentinel lymph node biopsy in N+ breast cancer with conversion into N0 after neoadjuvant chemotherapy［J］.Rev Esp Med Nucl Imagen Mol,2019,38(3):140-146.
[25]OSORIO-SILLA I,GAMEZ VALDAZO A,SANCHEZ MENDEZ JI,et al.Is it always necessary to perform an axillary lymph node dissection after neoadjuvant chemotherapy for breast cancer［J］.Ann R Coll Surg Engl,2019,101(3):186-192.
[26]KUEHN T,BAUERFEIND I,FEHM T,et al.Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy(SENTINA):a prospective,multicentre cohort study［J］.Lancet Oncol,2013,14(7):609-618.
[27]BOILEAU JF,POIRIER B,BASIK M,et al.Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer:the SN FNAC study［J］.J Clin Oncol,2015,33(3):258-264.
[28]BOUGHEY JC,SUMAN VJ,MITTENDORF EA,et al.Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer:the ACOSOG Z1071(Alliance)clinical trial［J］.JAMA,2013,310(14):1455-1461.
[29]CLASSE JM,LOAEC C,GIMBERGUES P,et al.Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients:the GANEA 2 study［J］.Breast Cancer Res Treat,2019,173(2):343-352.
[30]DONKER M,STRAVER ME,WESSELING J,et al.Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients:the MARI procedure［J］.Ann Surg,2015,261(2):378-382.
[31]CAUDLE AS,YANG WT,KRISHNAMURTHY S,et al.Improved Axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes:implementation of targeted Axillary dissection［J］.J Clin Oncol,2016,34(10):1072-1078.
[32]TEE SR,DEVANE LA,EVOY D,et al.Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer［J］.Br J Surg,2018,105(12):1541-1552.
[33]WONG SM,BASIK M,FLORIANOVA L,et al.Oncologic safety of sentinel lymph node biopsy alone after neoadjuvant chemotherapy for breast cancer［J］.Ann Surg Oncol,2021,28(5):2621-2629.
[34]朱文静,梁秋.新辅助化疗腋窝淋巴结临床完全缓解乳腺癌患者前哨淋巴结活检的可行性分析［J］.中国医师杂志,2019,(1):59-63. ZHU WJ,LIANG Q.The feasibility of sentinel lymph node biopsy after axillary lymph node clinical complete response［J］.Chinese Journal of Physicians,2019,21(1):59-63.
[35]DAMIN AP,ZANCAN M,MELO MP,et al.Sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with node-positive breast cancer:guiding a more selective axillary approach［J］.Breast Cancer Res Treat,2021,186(2):527-534.

Memo

Memo:
-
Last Update: 2021-12-31